FC
FATE icon

FORA Capital’s Fate Therapeutics FATE Stock Holding History

FORA Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,844
Closed -$317K – 958
2021
Q1 		$317K Sell
3,844
-7,115
-65% -$682K 0.1% 223
2020
Q4 		$997K Buy
10,959
+9,797
+843% +$608K 0.15% 155
2020
Q3 		$46K Sell
1,162
-1,916
-62% -$66.9K 0.03% 448
2020
Q2 		$106K Buy
3,078
+611
+25% +$18.2K 0.04% 481
2020
Q1 		$55K Buy
+2,467
New +$62.4K 0.01% 746

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

FORA Capital's FATE Position: Q2 2021 in Review

FORA Capital sold out of Fate Therapeutics (FATE) in Q2 2021, closing a stake of 3,844 shares — an estimated $317K sold.

FORA Capital first reported a position in FATE in Q1 2020 and held it in 5 quarters. The position peaked at $997K in Q4 2020. 272 funds tracked by Wall St. Rank hold FATE as of Q2 2021.

  • FORA Capital reported no remaining Fate Therapeutics position as of Q2 2021 after selling out during the quarter.
  • FORA Capital sold 3,844 Fate Therapeutics shares in Q2 2021, an estimated $317K.
  • FORA Capital first reported a position in Fate Therapeutics in Q1 2020 and held it in 5 quarters.
  • FORA Capital's Fate Therapeutics position peaked at $997K in Q4 2020.
  • 272 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2021.

Based on FORA Capital's 13F filing for Q2 2021, filed 16 Aug 2021.